Oryzon Genomics Q1 2026 Results, Drug Progress

Oryzon Genomics reported its financial results for the first quarter ended March 31, 2026, showing a net loss of $2.0 million and a cash position of $25.4 million. The company provided a corporate update highlighting significant progress in its clinical development programs. Notably, iadademstat, an oncology/hematology program, demonstrated highly encouraging clinical data in acute myeloid leukemia (AML) trials, with a 100% overall response rate in the ALICE-2 Phase Ib trial and a 67% composite complete remission rate in the FRIDA Phase Ib trial. Oryzon Genomics is also expanding iadademstat's clinical development into other hematological malignancies, solid tumors, and non-malignant hematology, including sickle cell disease and essential thrombocythemia. For its CNS program, vafidemstat, Oryzon Genomics is actively preparing for the United States — Food and Drug Administration protocol resubmission of the PORTICO-2 Phase III trial in aggression in Borderline Personality Disorder and advancing studies in schizophrenia and autism spectrum disorder. The company also strengthened its intellectual property portfolio for both iadademstat and vafidemstat with new patent grants from the United States — United States Patent and Trademark Office and other international patent offices. Rolando Gutiérrez-Esteinou was appointed Chief Medical Officer for CNS programs.